Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
29 participants
INTERVENTIONAL
2006-11-30
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034801
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
NCT00418171
A Study in the Treatment of Acute Mania
NCT00767715
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
NCT00191997
Short Term Rescue Study of Olanzapine
NCT00186017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ziprasidone hydrochloride
Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
B
olanzapine
Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ziprasidone hydrochloride
Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
olanzapine
Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).
Exclusion Criteria
* Have a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Aachen, , Germany
Pfizer Investigational Site
Augsburg, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
S. Arsenio, Salerno, Italy
Pfizer Investigational Site
Bari, , Italy
Pfizer Investigational Site
Guardiagrele (CH), , Italy
Pfizer Investigational Site
Lido Di Camaiore (LU), , Italy
Pfizer Investigational Site
Partinico (Pa), , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Siena, , Italy
Pfizer Investigational Site
Torino, , Italy
Pfizer Investigational Site
Trieste, , Italy
Pfizer Investigational Site
Terrassa, Barcelona, Spain
Pfizer Investigational Site
Alava, Vitoria, Spain
Pfizer Investigational Site
Granada, , Spain
Pfizer Investigational Site
Málaga, , Spain
Pfizer Investigational Site
Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1281147
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.